Loss of Tet1-Associated 5-Hydroxymethylcytosine Is Concomitant with Aberrant Promoter Hypermethylation in Liver Cancer

  • John P. Thomson
    1MRC Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom.
  • Raffaele Ottaviano
    1MRC Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom.
  • Elif B. Unterberger
    2Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.
  • Harri Lempiäinen
    3Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Arne Muller
    3Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Remi Terranova
    3Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Robert S. Illingworth
    1MRC Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom.
  • Shaun Webb
    4Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, United Kingdom.
  • Alastair R.W. Kerr
    4Wellcome Trust Centre for Cell Biology, University of Edinburgh, Edinburgh, United Kingdom.
  • Marcus J. Lyall
    5University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
  • Amanda J. Drake
    5University/BHF Centre for Cardiovascular Science, University of Edinburgh, Edinburgh, United Kingdom.
  • C. Roland Wolf
    6Medical Research Institute, University of Dundee, Ninewells Hospital & Medical School, Dundee, United Kingdom.
  • Jonathan G. Moggs
    3Preclinical Safety, Novartis Institutes for Biomedical Research, Basel, Switzerland.
  • Michael Schwarz
    2Department of Toxicology, Institute of Experimental and Clinical Pharmacology and Toxicology, University of Tübingen, Tübingen, Germany.
  • Richard R. Meehan
    1MRC Human Genetics Unit at the Institute of Genetics and Molecular Medicine at the University of Edinburgh, Edinburgh, United Kingdom.

説明

<jats:title>Abstract</jats:title> <jats:p>Aberrant hypermethylation of CpG islands (CGI) in human tumors occurs predominantly at repressed genes in the host tissue, but the preceding events driving this phenomenon are poorly understood. In this study, we temporally tracked epigenetic and transcriptomic perturbations that occur in a mouse model of liver carcinogenesis. Hypermethylated CGI events in the model were predicted by enrichment of the DNA modification 5-hydroxymethylcytosine (5hmC) and the histone H3 modification H3K27me3 at silenced promoters in the host tissue. During cancer progression, selected CGIs underwent hypo-hydroxymethylation prior to hypermethylation, while retaining H3K27me3. In livers from mice deficient in Tet1, a tumor suppressor involved in cytosine demethylation, we observed a similar loss of promoter core 5hmC, suggesting that reduced Tet1 activity at CGI may contribute to epigenetic dysregulation during hepatocarcinogenesis. Consistent with this possibility, mouse liver tumors exhibited reduced Tet1 protein levels. Similar to humans, DNA methylation changes at CGI in mice did not appear to be direct drivers of hepatocellular carcinoma progression, rather, dynamic changes in H3K27me3 promoter deposition correlated strongly with tumor-specific activation and repression of transcription. Overall, our results suggest that loss of promoter-associated 5hmC in liver tumors licenses reprograming of DNA methylation at silent CGI during progression. Cancer Res; 76(10); 3097–108. ©2016 AACR.</jats:p>

収録刊行物

  • Cancer Research

    Cancer Research 76 (10), 3097-3108, 2016-05-12

    American Association for Cancer Research (AACR)

被引用文献 (3)*注記

もっと見る

詳細情報 詳細情報について

問題の指摘

ページトップへ